WC
KBIO

Wexford Capital’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Wexford Capital’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-39,062
Closed -$847K – 224
2014
Q1 		$847K Buy
39,062
+584
+2% +$16.9K 0.06% 115
2013
Q4 		$1.36M Buy
38,478
+3,670
+11% +$123K 0.12% 93
2013
Q3 		$1.26M Buy
+34,808
New +$1.59M 0.1% 104

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Wexford Capital's KBIO Position: Q2 2014 in Review

Wexford Capital sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q2 2014, closing a stake of 39,062 shares — an estimated $847K sold.

Wexford Capital first reported a position in KBIO in Q3 2013 and held it in 3 quarters. The position peaked at $1.36M in Q4 2013. 43 funds tracked by Wall St. Rank hold KBIO as of Q2 2014.

  • Wexford Capital reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q2 2014 after selling out during the quarter.
  • Wexford Capital sold 39,062 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q2 2014, an estimated $847K.
  • Wexford Capital first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q3 2013 and held it in 3 quarters.
  • Wexford Capital's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $1.36M in Q4 2013.
  • 43 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q2 2014.

Based on Wexford Capital's 13F filing for Q2 2014, filed 13 Aug 2014.